CN |CAS  
 
  Home | Links | Site map
 
Home About Us News Organization Research Faculty Publication Education&Trainning Contact
  Research
Location: Home > Research
 
 
Research
Target
Discovery
Development
Translation
 
SIMM Class 1.1 Anti-cancer Investigational New Drug Bisthianostat Approved into Clinical Trial
Update time: 2016-08-22
Close
Text Size: A A A
Print

Recently, The Bisthianostat, a class 1.1 anti-cancer Investigational New Drug(IND), independently developed by Shanghai Institute of Materia Medica (SIMM), CAS was approved into clincal trial by the State Food and Drug Administration of China (CFDA). 

Bisthianostat is a new type of bisthiazol-based pan- HDAC (histone deacetylase) inhibitor, which was developed by SIMM researchers and preclinical developed in collaboration with researchers from pharmaceutical companies.

 
weimoban
About Us News Research Faculty Education&Trainning Organization Contact
Brief Introduction
History
Address from the Director
Directors
Administration
Research
Events
Int'l cooperation
Target
Discovery
Development
Translation
Academician
PI
Graduate Students
Post Graduate Students